Oncofetal fibronectin as a marker for health and disease
First Claim
1. A method of detecting the presence of cancerous or pre-cancerous cervical cells in a subject, comprising:
- testing for an oncofetal fibronectin indicating molecule in a sample from a subject, wherein;
the sample is selected from among urine, cervical interstitial fluid, blood, plasma and serum; and
an oncofetal fibronectin positive sample indicates the presence of cancerous or pre-cancerous cervical cells in the subject.
5 Assignments
0 Petitions
Accused Products
Abstract
Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronection for selection of concepti are provided.
124 Citations
31 Claims
-
1. A method of detecting the presence of cancerous or pre-cancerous cervical cells in a subject, comprising:
-
testing for an oncofetal fibronectin indicating molecule in a sample from a subject, wherein;
the sample is selected from among urine, cervical interstitial fluid, blood, plasma and serum; and
an oncofetal fibronectin positive sample indicates the presence of cancerous or pre-cancerous cervical cells in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A method of detecting an oncofetal fibronectin indicating molecule in tissue or cells of a subject, comprising:
-
administering to a subject a fibronectin or oncofetal fibronectin binding partner conjugated to an imaging moiety, whereby the conjugate localizes to tissue or cells in the subject containing an oncofetal fibronectin indicating molecule; and
detecting the localization of the conjugate within the subject, thereby detecting the oncofetal fibronectin indicating molecule in tissue or cells of the subject, wherein detection is indicative of cancer or a disease state characterized by the presence of oncofetal fibronectin. - View Dependent Claims (24)
-
-
25. A method of treating tumorous tissue in a subject, comprising topically administering to a subject a fibronectin or oncofetal fibronectin binding partner, whereby the binding partner localizes to surfaces on the subject containing an oncofetal fibronectin indicating molecule, whereby the localized binding partner causes cell death or inhibits cell growth, whereby the cell death or cell growth inhibition caused by the binding partner inhibits tumor proliferation in the subject.
-
26. A method for inhibiting the recurrence of neoplastic disease in a subject, comprising:
-
treating a subject for neoplastic disease; and
administering to the treated subject a fibronectin or oncofetal fibronectin binding partner, whereby recurrence of neoplastic disease is inhibited. - View Dependent Claims (27)
-
-
28. A method of determining the overall health state of a subject, comprising testing for the presence of an oncofetal fibronectin indicating molecule in a sample from a subject, wherein:
-
the presence of oncofetal fibronectin indicating molecule in the sample indicates that the subject has a disease characterized by the presence of oncofetal fibronectin; and
the absence of oncofetal fibronectin indicating molecule indicates that the subject is free of a disease characterized by oncofetal fibronectin. - View Dependent Claims (29, 30, 31)
-
Specification